Objective: We evaluated association of variants in the sterol regulatory elementbinding factor 1 gene (SREBF1) with type 2 diabetes. Due to the previous inconclusive quantitative trait associations, we also did studies of intermediate quantitative phenotypes.
he sterol regulatory elementbinding factor (SREBF1) gene encodes the transcription factors SREBP-1a and -1c by differential transcription start sites (1) . SREBP-1a and -1c, and the third family member SREBP-2, are implicated in regulation of cholesterol and fatty acid synthesis [reviewed in (2) ]. SREBP-1c is in humans expressed in most tissues including liver, adipose tissue and skeletal muscle, while SREBP-1a is expressed mainly in the spleen and intestine (3) . SREBP-1c is a mediator of insulin action in liver, adipose tissue and skeletal muscle (4) with the ability to activate lipogenic genes, glucokinase and hexokinase in these metabolic tissues (5, 6) . SREBP-1c thereby induces both glucose utilization and lipid metabolism suggesting that a low level of SREBP-1c is a contributing factor in the pathogenesis of insulin resistance and type 2 diabetes. In the adipose tissue and skeletal muscle of type 2 diabetic patients, expression of SREBP1c is indeed decreased (7) . This is consistent with studies of the SREBP1c-specific knock-out mice showing a mild hyperglycaemic phenotype (8) .
In contrast, since SREBP-1c promotes fatty acid synthesis and lipogenesis, SREBP-1c over-expression could moreover be a factor responsible for insulin resistance through overaccumulation of lipids also leading to lipotoxicity (9) . Interestingly, increased expression of SREBP-1c in the liver has been observed in animal models of obesity and type 2 diabetes (10) .
Genome-linkage scans have linked the 17p11 region comprising SREBF1 to type 2 diabetes (11) and case-control studies including 1,000-2,000 participants have consistently associated SREBF1 with type 2 diabetes, although with different variants in linkage disequilibrium (12) (13) (14) (15) . Recent genome-wide association studies (GWAS) did, however, not report SREBF1 as a type 2 diabetes locus (16) (17) (18) (19) (20) . Furthermore, associations with obesity (12) , circulating total and LDLcholesterol (13) , HDL-cholesterol (15) , and plasma glucose levels (14) have been reported, yet none of these associations have been conclusively replicated (12, 13, 15) .
In the present study we intended to evaluate association between SREBF1 variants and type 2 diabetes. Due to the prior inconsistent quantitative trait associations, we additionally aimed to establish a quantitative metabolic phenotype in statistically well-powered cohorts of middle-aged Danes. Given the biological evidence we primarily hypothesized that SREBF1 variants influenced peripheral insulin action.
SUBJECTS, MATERIALS AND METHODS
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RESULTS
Initially we analyzed the pattern of LD between the four genotyped variants in SREBF1 and we observed relatively high LD between rs1889018, rs2297508 and rs11868035 (R 2 =0.6-0.8) (Figure 1 ). The four SREBF1 variants were assessed for potential associations with type 2 diabetes in a case-control study involving 2,980 type 2 diabetic patients and 4,522 glucose-tolerant control subjects ( Table 1 (Table  1) . We performed meta-analyses of the unadjusted association with type 2 diabetes including the present study, all previously published studies (12) (13) (14) (15) and online data from two GWAS (18,19). The minor alleles of rs2297508, rs1889018 and rs11868035 all associated with a modest increase in type 2 diabetes susceptibility (OR 1.06-1.08, P<0.01) ( Figure 2 ). Tests of between-study homogeneity showed no heterogeneity for rs1889018 and rs11868035 variants but some heterogeneity for rs2297508 (P=0.02).
To evaluate the metabolic phenotype of the type 2 diabetes susceptibilityallele carriers the four SREBF1 variants were investigated in the populationbased Inter99 sample involving 5,970 middle-aged treatment-naïve individuals (Table 2) . At the population level, the Gallele of rs2297508 associated with a slight increase in fasting plasmaglucose level (P=0.02) and with a slightly increased plasma-glucose at 30 and 120 minutes during an OGTT (P=0.006 and P=0.001, respectively). In addition, we observed a strong association to a higher 120-min seruminsulin during an OGTT (P=0.0002) and with a slightly increased HbA 1c level (P=0.006) ( Table 2 ). The minor alleles of the rs1889018 and rs11868035 variants showed similar associations with glycemia (Appendix table 2) .
A surrogate measure of insulin resistance was reported as the BIGTTinsulin sensitivity index (BIGTT-S i ) (26) and as the homeostasis model assessment index (HOMA-IR). We observed a decreased insulin sensitivity assessed by BIGTT-S i in carriers of the minor rs1889018 C-allele (P=0.03) (Appendix table 2) and this association was strengthened after adjustment for the level of insulin release (P=0.006).
Further analyses of metabolic phenotypes were performed in the ADDITION screening cohort consisting of 8,662 subjects at high risk of type 2 diabetes. We replicated the association of the G-allele of rs2297508 with a 0.45% increase in HbA 1c per allele (P=0.008) ( Table 2 ). In the ADDITION study we also found nominal associations with decreased BMI in rs2297508 minor G-allele carriers (Table 2 ) and increased fasting serumcholesterol level for carriers of the minor allele of rs11868035 (Appendix table 3 ). The rs4925118 variant did not associate with examined metabolic traits ( Table 1 , Appendix tables 2-3).
Haplotype association analyses did not add further to single variant analyses (Appendix table 5 ).
DISCUSSION
In the present study we report associations of sequence variation in SREBF1 with a modest increase in type 2 diabetes risk. In the well-characterized population-based Inter99 sample of middle-aged treatment-naïve individuals we report strong associations for the diabetes risk-allele carriers with higher plasma-glucose and serum-insulin after an oral glucose load as well as with a slight increase in HbA 1c . The latter was supported by association with HbA 1c in the Danish ADDITION study. Also variants in SREBF1 associate with BIGTT-Si which is a well-documented surrogate measure of insulin sensitivity (26).
Since the transcription factor SREBP-1c is a mediator of insulin action in skeletal muscle, adipose tissue and liver, it is conceivable that a polymorphism conferring a subtle lossof-function may affect the expression of SREBP-1c, could contribute to the insulin resistance phenotype. The observed effects are evident in the postprandial state. Enzymes involved in the glucose metabolism are highly regulated by SREBP-1c, and if down-regulated due to a mild SREBP-1c dysfunction the glucose metabolism would likely be impaired in the peripheral tissues potentially leading to post-prandial hyperglycemia and insulin resistance.
Prior association studies have shown an impact of the rs2297508 variant (12, 15) , the rs11868035 variant (13, 14) and rs2236513, rs6502618, rs1889018 variants (14) in SREBF1 on risk of type 2 diabetes. All these variants are in substantial LD (HapMap: R 2 0.67-0.95). In the present report we replicate associations of rs2297508, rs11868035 and rs1889018 with type 2 diabetes. As none of the recent GWAS (16) (17) (18) (19) (20) reported SREBF1 as a type 2 diabetes locus we engaged in meta-analyses of the present data and previously published studies (12) (13) (14) (15) as well as all online available data from GWAS (18, 19) . In combined analyses we showed discreet increases in type 2 diabetes risk for all three variants. However, it should be pointed out that meta-analysis which in principle might be expected to provide conclusive answers, may be compromised by heterogeneity of ethnicity and outcome phenotypes besides publication and ascertainment bias. Moreover, the present meta-analyses include imputed data and data based on perfect LD with another marker, yet data from three other GWAS (16, 17, 20) were not available. Besides, we are in the metaanalyses not able to adjust for the effect of confounding factors such as age, sex and BMI, which further weakens the analysis; in fact in the present report the association with type 2 diabetes was abolished when not adjusting for the effect of age and sex. Therefore, cautious interpretations of these metaanalyses are crucial.
Previous reports regarding associations between SREBF1 variants and quantitative metabolism have been inconclusive. One study has indicated an association of the rs11868035 variant with increased fasting total and LDL-cholesterol levels (13). In contrast, two studies did not show any association of the rs2297508 variant with fasting cholesterol levels (12, 15) . We found nominal associations of rs11868035 variant with increased fasting serum-cholesterol level and the rs2297508 and rs1889018 variants with decreased BMI in the ADDITION study of subjects in high risk of type 2 diabetes, however these associations were not observed in the populationbased Inter99 study. These ambiguities may be due to the diversity of the populations e.g. accentuation of associations in the ADDITION cohort due to the high-risk selection procedure, yet could more likely be a result of statistical type I errors. In fact, association with obesity has also previously been conflicting (12, 13, 15, 18 ) and the present study does not support previous associations to obesity-related traits. Moreover, a recent study found borderline significant associations of the minor alleles of the rs1889018 and rs2236513 variants with higher plasma-glucose level at fasting and 2 hours after an oral glucose challenge (14) . In the current study we substantiate these findings. Since published studies do not investigate the exact same variants in SREBF1 these somewhat inconsistent reports may be explained by population-specific differences in LD pattern, but could also be caused by discrepancies in the examined populations, e.g. environmental modifying effects, or by statistical type I or II errors.
So far the causal variant giving rise to the described associations has not been identified. Even though we present data supporting an association with type 2 diabetes and glycemia we recognize that the present results may be falsely positive due to the fact that no correction for multiple testing was applied. Yet, we argue that based on previous reports a SREBF1 effect on risk of type 2 diabetes was the primary hypothesis of this study and as the association with glycemia, evaluated by HbA 1c , was supported by association in an independent cohort, no correction is strictly needed.
In conclusion, we associate variants in SREBF1 with a slight increase in type 2 diabetes risk. Of novelty, we present data suggesting an association with glycemia in the general population of middle-aged people, possibly due to a decreased SREBP-1c function in individuals carrying the as yet undefined causal variant. . Homeostasis model assessment of insulin resistance (HOMA-IR) (mmol/l×pmol/l) was calculated as fasting plasma-glucose (mmol/l) multiplied by fasting serum-insulin (pmol/l) and divided by 22.5. BIGTT-insulin sensitivity index (BIGTT-S i ) uses information on sex and BMI combined with analysis of p-glucose and s-insulin levels at the time points 0, 30, and 120 min to provide an index for S i which highly correlates with indexes obtained during an IVGTT, and were calculated as described elsewhere (26). B, blood; P, plasma; s, serum. Estimated odds ratios (95% CI) of type 2 diabetes in minor allele carriers of rs1889018 (a), rs2297508 (b) or rs11868035 (c) of SREBF1 in combined analyses of all currently available studies. Odds ratios (95% CI) of type 2 diabetes are rs1889018: 1.06 (1.01-1.11), P=0.01; rs2297508: 1.08 (1.03-1.14), P=0.001; rs11868035: 1.07 (1.02-1.13), P=0.006. No heterogeneity between studies was observed for the rs1889018 and rs11868035 variants (P=0.3 and P=0.2, respectively). Some heterogeneity was found for rs2297508 (P=0.02). Numbers in square brackets designate numbers of type 2 diabetes patients and control subjects. Numbers in round brackets indicate the reference number. * Genotypes were based on the rs9899634 variant which is in perfect LD with rs1889018 (HapMap: R 2 =1). Data were obtained at http://www.broad.mit.edu/diabetes/. † Genotypes are based on imputation and were obtained at http://www.wtccc.org.uk/.
